Cargando…

Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report

Plasma cell disorders (PCDs) are identified in the clinical lab by detecting the monoclonal immunoglobulin (M-protein) which they produce. Traditionally, serum protein electrophoresis methods have been utilized to detect and isotype M-proteins. Increasing demands to detect low-level disease and new...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murray, David L., Puig, Noemi, Kristinsson, Sigurdur, Usmani, Saad Z., Dispenzieri, Angela, Bianchi, Giada, Kumar, Shaji, Chng, Wee Joo, Hajek, Roman, Paiva, Bruno, Waage, Anders, Rajkumar, S. Vincent, Durie, Brian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873248/ https://www.ncbi.nlm.nih.gov/pubmed/33563895 http://dx.doi.org/10.1038/s41408-021-00408-4

Ejemplares similares

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma
por: Puig, Noemí, et al.
Publicado: (2022)

Sensitive multiple myeloma disease monitoring by mass spectrometry
por: Santockyte, Rasa, et al.
Publicado: (2021)

Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement
por: Murray, David, et al.
Publicado: (2019)

Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma
por: Foureau, David, et al.
Publicado: (2021)

P879: EXENT AND FLC MASS SPECTROMETRY FOR SEROLOGICAL IDENTIFICATION AND QUANTIFICATION OF MONOCLONAL IMMUNOGLOBULINS IN MULTIPLE MYELOMA
por: Huhn, S., et al.
Publicado: (2022)

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry
por: Noori, Somayya, et al.
Publicado: (2023)

Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma
por: Micallef, Johann, et al.
Publicado: (2010)

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2023)

MINIMAL RESIDUAL DISEASE IN PERIPHERAL BLOOD ASSESSED BY MASS SPECTROMETRY
por: Puig, Noemi
Publicado: (2022)

MASS SPECTROMETRY AS A TOOL FOR MINIMAL RESIDUAL DISEASE DETECTION IN THE BLOOD OF MYELOMA PATIENTS
por: Jacobs, J.F.M.
Publicado: (2023)

PB2139: MONITORING OLIGOSECRETORY MULTIPLE MYELOMA USING MALDI-TOF MASS SPECTROMETRY
por: Berlanga, Oscar, et al.
Publicado: (2023)

Liquid Chromatography Mass Spectrometry-Based Metabolite Pathway Analyses of Myeloma and Non-Hodgkin’s Lymphoma Patients
por: Medriano, Carl Angelo D., et al.
Publicado: (2017)

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives
por: Lonial, S, et al.
Publicado: (2016)

Rapid discrimination of multiple myeloma patients by artificial neural networks coupled with mass spectrometry of peripheral blood plasma
por: Deulofeu, Meritxell, et al.
Publicado: (2019)

A Personalized Mass Spectrometry–Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM)
por: Liyasova, Mariya, et al.
Publicado: (2021)

Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma
por: Greenberg, Alexandra J., et al.
Publicado: (2013)

Application of Advanced Mass Spectrometry-Based Proteomics to Study Hypoxia Driven Cancer Progression
por: Vinaiphat, Arada, et al.
Publicado: (2021)

Two-dimensional mass spectrometry: new perspectives for tandem mass spectrometry
por: van Agthoven, Maria A., et al.
Publicado: (2019)

Multiple myeloma current treatment algorithms
por: Rajkumar, S. Vincent, et al.
Publicado: (2020)

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
por: Mateos, María-Victoria, et al.
Publicado: (2020)

Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN)
por: Liu, Jin, et al.
Publicado: (2020)

Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

High Levels of Peripheral Blood Circulating Plasma Cells as a Specific Risk Factor for Progression of Smoldering Multiple Myeloma
por: Bianchi, Giada, et al.
Publicado: (2012)

Accelerator mass spectrometry
Publicado: (1995)

Modern mass spectrometry
por: Barnard, George P
Publicado: (1953)

The Encyclopedia of Mass Spectrometry
por: Armentrout, Peter, et al.
Publicado: (2003)

Optomechanical mass spectrometry
por: Sansa, Marc, et al.
Publicado: (2020)

Mass Spectrometry Imaging
por: Shimma, Shuichi
Publicado: (2022)

Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma
por: Damasceno, Daniela, et al.
Publicado: (2021)

History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study
por: Lindqvist, Ebba K., et al.
Publicado: (2016)

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project
por: Usmani, Saad Z., et al.
Publicado: (2018)

Charge variant native mass spectrometry benefits mass precision and dynamic range of monoclonal antibody intact mass analysis
por: Bailey, Aaron O., et al.
Publicado: (2018)

Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: impact on prognosis and myeloma dissemination
por: Li, Zhenhai, et al.
Publicado: (2020)

Mass Spectrometry Approaches for Identification and Quantitation of Therapeutic Monoclonal Antibodies in the Clinical Laboratory
por: Ladwig, Paula M., et al.
Publicado: (2017)

A Comparison of Different Sample Processing Protocols for MALDI Imaging Mass Spectrometry Analysis of Formalin-Fixed Multiple Myeloma Cells
por: Casadonte, Rita, et al.
Publicado: (2023)

P37 MULTIPLE MYELOMA MONITORING FROM ARCHIVED SERUM PROTEIN ELECTROPHORESIS GELS BY MASS SPECTROMETRY AND DE NOVO SEQUENCING
por: Noori, S., et al.
Publicado: (2023)

Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)

Mass Spectrometry Group Has Mass Appeal
por: Eubanks, Mary
Publicado: (2004)

Metabolic Vulnerabilities in Multiple Myeloma
por: Lim, Julia S. L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0ndmmfqv9sg9h9i04cod52c6jh